Tag
The PIONIR randomized crossover trial demonstrates that a specific Tasty&Healthy diet significantly reduces fecal calprotectin levels, a marker of gut inflammation, in first-degree relatives at high risk for Crohn’s disease, sugge
A Swedish cohort study reveals increased risk of inflammatory bowel disease in relapsing-remitting multiple sclerosis patients treated with rituximab compared to other therapies and the general population, underscoring the need for gastroin
Intestinal inflammation disrupts gut microbial metabolism of dietary antigens, promoting food sensitization and mast cell–mediated adverse reactions, which may explain frequent food intolerances in IBD patients.
A nationwide cohort study reveals that in IBD patients, colorectal cancer risk increases notably with multiple affected relatives, challenging current guidelines prioritizing early-onset family history for surveillance.
Childhood exposure to siblings with Crohn’s disease significantly raises disease risk, linked to distinct gut microbiome changes that may drive disease onset through immune modulation.
This multicenter retrospective study examines colorectal dysplasia and malignancy outcomes in patients with primary sclerosing cholangitis and inflammatory bowel disease undergoing liver transplantation and colectomy, revealing comparable 5
This study elucidates how genetic differences in acetaldehyde metabolism modify the risk of alcohol-associated inflammatory bowel disease (IBD), highlighting personalized prevention strategies.
IBDome offers a comprehensive multiomic atlas integrating molecular, histopathological, and clinical data, advancing the understanding and precision treatment of Crohn’s disease and ulcerative colitis.
New data identify GPR15L as an epithelial host-defense peptide that reshapes the colonic microbiota, reduces experimental colitis, and may have therapeutic relevance in inflammatory bowel disease.
Recent Mendelian randomization analyses demonstrate causal effects of increased BMI and inflammatory bowel disease on hidradenitis suppurativa risk, elucidating modifiable contributions beyond genetic correlations with psoriasis and systemi
This review evaluates the IBD-BOOST digital cognitive behavioural self-management intervention’s design, trial outcomes, process evaluation, and clinical implications for managing fatigue, pain, and faecal incontinence in IBD.
The IL23R1142G>A genetic variant strongly predicts paradoxical psoriasis in inflammatory bowel disease patients undergoing anti-TNFα therapy, guiding personalized treatment decisions.
A recent cross-sectional study reveals that alterations in gut microbiota correlate more strongly with impaired health-related quality of life in IBD patients than clinical disease activity, suggesting novel microbial therapeutic targets be
Recent research elucidates how smoking modulates gut microbiota and immune responses differently in ulcerative colitis and Crohn’s disease, explaining its protective effect in UC but detrimental role in CD.
High fructose intake can directly activate immune cells, worsening intestinal inflammation linked to IBD, but the diabetes drug metformin shows promise in reversing these effects.
The TUSCANY-2 phase 2b trial evaluated afimkibart, a novel anti-TL1A antibody, in moderately-to-severely active ulcerative colitis, demonstrating favorable safety and clinically meaningful remission rates using modified Mayo scores despite
